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2. Supporting figures 
 
Figure S3. Control transport experiments in HeLa cells. Confocal micrographs of HeLa cells incubated 
with: A) Pyranine (5 µM) and only cage (5 µM). B) TmR4 (5 µM) and Pyranine (5 µM). C) Pyranine (5 µM). 
D) TmR4C (5 µM). DIC on the left and merge of fluorescence channels [Pyranine emission (green) + TAMRA 
emission (red) + Hoechst 33342 emission (blue)] on the right. HeLa cells were treated first with Hoechst 33342 
for 30 min, washed (HKR buffer, 1x) and then incubated with the different controls in HKR buffer for 30 min 
at 37 ºC. The cells were finally washed (HKR buffer, 3x) and then observed under the confocal microscope. 
 
Figure S4. Transport experiments in HeLa cells with hybrids TmAC and TmR8C. Confocal micrographs of 
HeLa cells incubated with: A) 5 µM of TmAC and 5 µM Pyranine B) 5 µM of TmR8C and 5 µM Pyranine. DIC 
on the left and merge channels [Pyranine emission (green) + TAMRA emission (red) + Hoechst 33342 
emission (blue)] on the right. HeLa cells were treated first with Hoechst 33342 for 30 min, washed (HKR 
buffer, 1x) and then incubated with the different mixtures in HKR buffer for 30 min at 37 ºC. The cells were 
finally washed (HKR buffer, 3x) and then observed under the confocal microscope. Toxicity was evident by 
the morphological alterations such as rounding or nuclear swelling (A and B) and the lower number of cells 




· 1 Hour incubation time: 
 
 
· 24 Hours incubation time: 
 
Figure S5. Viability assay in HeLa (A, B, C, G, H, I) and Vero cells (D, E, F, J, K, L) with the different 
peptides TmR4C (A, D, G, J), AcR4C (B, E, H, K) and pyranine (C, F, I, L) at different concentrations after 1 
hour incubation time (A, B, C, D, E, F) and after 24 hours incubation time (G, H, I, J, K, L) at 37 ºC. Error bars 






Figure S6. A) and D) Fluorescence titration of pyranine with the peptide/cage complexes AcR4C (A) and 
TmR4C (D) in phosphate buffer (pH 7). Arrow indicates the decrease of pyranine fluorescence with increasing 
amounts of peptide. The right peak in D corresponds to the TAMRA emission from TmR4C. B), C) and E) 510 
nm fluorescence emission and curve fit for the titration of pyranine with AcR4C (B, C) or with TmR4C (E) in 
phosphate buffer pH 7. The best fit to the data using nonlinear analysis with Origin 8.5 to the Hill 1 equation: 
KD= 189 nM for AcR4C and KD= 12.6 µM for TmR4C. In C, fitting was done with a fixed value of n = 1, and KD 
for AcR4C under these conditions was 149 nM. The small peak observed in A) at about 480 nm at the higher 







Figure S7. Dose-response transport experiments of pyranine in HeLa cells and pyranine delivery with 
the acetylated peptide. Confocal micrographs of HeLa cells incubated with: A) TmR4C (5 µM), B) TmR4C (5 
µM) and Pyranine (2.5 µM), C) R4C (5 µM) and Pyranine (5 µM), D) TmR4C (5 µM) and Pyranine (10 µM). 
DIC on the left and merge channels [Pyranine emission (green) + Tm emission (red)] on the right. HeLa cells 
were incubated with the different components in HKR buffer for 30 min at 37 ºC. The cells were finally 
washed (HKR buffer, 3x) and then observed under the confocal microscope. E) The acetylated version, AcR4C, 
is also able to deliver pyranine in HeLa cells. Cells were incubated with AcR4C (5 µM) and pyranine (5 µM; 





Figure S8. Quantification of the uptake of TmR4C (15 µM) and pyranine (15 µM) in Vero cells under different 
conditions: 37 ºC (control), DYN (dynasore, 80 µM) and 4 ºC. A) and C) median fluorescence intensity (MFI) 
corresponding to pyranine fluorescence (A) or TmR4C (C). B) and D) uptake normalized to the control of 
TmR4C with pyranine incubated at 37 ºC, corresponding to pyranine (B) or TmR4C (D). The last two bars in all 







Figure S9. Internalization experiments in Vero cells. A) Vero cells incubated for 30 min with pyranine (10 
µM, green) and only cage C. B) Vero cells incubated for 30 min with pyranine (10 µM, green) and AcR4. C) 
and D) Sequential addition of pyranine and AcR4C to Vero cells. Cells were incubated for ten minutes with 
pyranine before the dropwise addition of AcR4C to a final concentration of 10 µM and incubation for 30 
minutes at 37 oC. Cells were stained with propidium iodide before imaging to detect membrane damage. Left 
panel: BF; second panel: pyranine (green); third panel: propidium iodide (red); right panel: merge of 
fluorescence channels. Images show internalization of pyranine and the aggregation of the pyranine/peptide 







Figure S10. A) Viability assay in HeLa cells with AcR4C at different concentrations after 24 hours incubation 
time at 37 ºC. B) Viability comparison between AcR4C at 20 µM and AcR4C at 20 µM in presence of 20 µM of 








Figure S11. TAMRA competition experiments in Vero cells. Confocal micrographs of Vero cells incubated 
with: A) AcR4C (10 µM) combined with pyranine (20 µM, green) in the presence of TAMRA (20 µM, red) B) 
only TAMRA (20 µM, red channel). C) AcR4C (10 µM) in the presence of TAMRA (20 µM, red channel). Left 
panels correspond to DIC images. Vero cells were treated with the different conditions in HKR buffer for 30 
min at 37 ºC. The cells were finally washed (HKR buffer, 3x) and then observed under the confocal 
microscope. D) Fluorescence spectra of the titration of 30 nM TAMRA fluorophore with increasing 







Figure S12. Transport experiments of Carboxyfluorescein (CF) in HeLa cells. Confocal micrographs of 
HeLa cells incubated with: A) TmR4C (5 µM) and Carboxyfluorescein (5 µM). B) TmR4 (5 µM) and 
Carboxyfluorescein (5 µM). DIC on the left and merge channels [Carboxyfluorescein emission (green) + Tm 
emission (red)] on the right. HeLa cells were incubated with the different components in HKR buffer for 30 
min at 37 ºC. The cells were finally washed (HKR buffer, 3x) and then observed under the confocal 
microscope. 
 
Figure S13. A) and C): Fluorescence spectra of the titration of CF with in AcR4C (A) or with TmR4C (C) in 
phosphate buffer (pH 7). Arrow indicates the decrease of CF fluorescence with increasing amounts of peptide. 
The right peak in C correspond to the TAMRA emission from TmR4C. B) and D) 516 nm fluorescence 
emission and curve fit for the titration of CF with AcR4C (B) or with TmR4C in phosphate buffer (pH 7). The 
best fit to the data using nonlinear analysis with Origin 8.5 to the Hill 1 equation: KD= 16.2 µM for AcR4C and 




Figure S14. A), C) and E): Fluorescence spectra of the titration of Alexa Fluor dyes with AcR4C. Arrows 
indicate the decrease of fluorophore emission with increasing amounts of AcR4C. B), D) and F) Fluorescence 
emission at the maximum of each fluorophore (513 nm for Alexa Fluor 488, 570 nm for Alexa Fluor 546 and 
603 nm for Alexa Fluor 568), and curve fit for the titration with AcR4C in phosphate buffer (pH 7). A), B): 
Alexa Fluor 488; C), D): Alexa Fluor 546; E), F): Alexa Fluor 568. The best fit to the data using nonlinear 
analysis with Origin 8.5 to the Hill 1 equation: KD= 6 µM for Alexa Fluor 488, KD= 1.37 µM for Alexa Fluor 







Figure S15. Pyranine fluorescence emission spectra of the aliquots taken from the U-Tube trans buffer at 
different times (10 mM NamHnPO4, 100 mM NaCl, pH 7.4). A) Pyranine alone (200 µM). B) Pyranine (200 





Figure S16. A) Absorption spectra of pyranine in buffers of different pH. B) Ratio of the absorbance at 450 
and 405 nm plotted as a function of pH. C) Ratiometric method for determining the pKa (see experimental 






Figure S17. pH studies in Vero cells A) Ratiometric imaging after pH clamping with nigericin of Vero cells 
incubated with 10 µM pyranine and 10 µM TmR4C. Top row (BF) shows bright field images. The second 
(PyrH) and third (Pyr-) rows show the emission of pyranine after excitation at 405 nm or 488 nm, respectively. 
Finally, the bottom row shows the processed images. B) Mean ratio values were obtained for each field and 
plotted against pH. Box and whisker plot of each dataset, green points represent individual observations. C) 





3. Materials and methods 
Chemicals were purchased from Carbosynth, Iris Biotech, Sigma Aldrich, Alfa Aesar, Stream Chemicals and 
Novabiochem and used without further purification. 
Commercially available 2-Chlorotrityl chloride resin, Fmoc-Ahx-OH, Fmoc-O2Oc-OH, Fmoc-L-Ala-OH, 
Fmoc-L-Leu-OH, Fmoc-L-Arg(pbf)-OH, triisopropylsilane (TIS), Disopropylethyl amine (DIEA), Nigericin 
and 8-Hydroxypyrene-1,3,6-trisulfonic acid trisodium salt (pyranine) were obtained from Sigma-Aldrich. 
MTT and MES (2-(N-morpholino)ethanesulfonic acid) were purchased from Alfa Aesar; 5(6)-
Carboxyfluorescein (CF) and 5-Carboxytetramethyl rhodamine (TAMRA) were available from Carbosynth. 
L-α-phosphatidylglycerol (Egg, Chicken) (sodium salt) was purchased from Avanti Polar Lipids and N-
HATU from Glentham life sciences. N-HBTU was obtained from Iris. Hoechst 33342 Trihydrochloride 
Trihydrate, Alexa Fluor dyes (488, 546 and 594) and Dulbecco’s Modified Eagle’s Medium (4500 mg/L 
glucose, L-glutamine, sodium pyruvate and sodium bicarbonate) were purchased in ThermoFisher. HEPES 
[4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid)] was purchased from TCI Chemicals. 
The solvents for organic synthesis were of reagent grade. Dry solvents were bought from Sigma-Aldrich. 
N,N-dimethylformamide and trifluoroacetic acid were purchased from Scharlau, dichloromethane from 
Panreac and acetonitrile from Merck. Water was deionized and purified on a Millipore Milli-Q Integral 
system. 
The removal of solvents under reduced pressure was carried out on a rotary evaporator Büchi R-210 
equipped with a thermostated bath B-491, a vacuum regulator V-850, and a vacuum pump V-700.  
Purification of products was accomplished using reversed-phase high-performance liquid chromatography 
(RP-HPLC) using an Agilent Technologies 1160 Infinity using H2O (+ 0.1% TFA) and CH3CN (+ 0.1% 
TFA) as eluents and a Luna (C18)-Phenomenex column and on Jasco LC-4000 with an Agilent Eclipse 
XDB-C18 column. 
High-performance liquid chromatography coupled with mass spectrometry (HPLC-MS) analyses were 
carried out on Agilent Technologies 1260 Infinity II associated with a 6120 Quadrupole LC-MS using an 
Agilent SB-C18 column or on DIONEX Ultimate 3000 U-HPLC+ (Thermo Scientific) with an Acclaim 
RSLC 120-C18 column with Solvent A:Solvent B gradients between 5:95 (Solvent A: H2O with 0.1% TFA; 
Solvent B: CH3CN with 0.1% TFA). 
Fluorescence measurements were performed using a Varian Cary Eclipse fluorometer and UV-Vis spectra 
were measured in an Agilent 8453 UV-Vis diode-array spectrophotometer or a Biochrom Libra S60 UV-vis 
spectrophotometer. 
For taking confocal microscopy images a Dragonfly confocal spinning-disk system mounted on a Nikon 
Eclipse Ti-E equipped with an Andor Zyla 4.2 PLUS sCMOS digital camera was used.  




A Tecan Infinite F200Pro microplate reader was used to measure directly in Costar cell culture 96-well 
plates UV-Vis absorbance for the MTT viability assays. 
Flow cytometry was performed on a Guava easyCyteTM cytometer. Data analysis was performed with InCyte 
software included in GuavaSoft 3.2 (Millipore). 
The “U-tubes” were house made.  
 
ABBREVIATIONS: 
Ahx: 6-aminohexanoic acid; Arg: Arginine; calcd: calculated; CF: carboxyfluorescein; DMEM: Dulbecco's 
Modified Eagle Medium; DIEA: N,N-Diisopropylethylamine; DMF: N,N-Dimethylformamide; DYN: 
Dynasore; EYPG: Egg yolk phosphatidylglycerol; FBS: Fetal bovine serum; Fmoc: 9-
Fluorenylmethoxycarbonyl; HEPES: 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; HKR: HEPES-
Krebs-Ringer buffer; Leu: Leucine; MES: 2-(N-morpholino)ethanesulfonic acid; MTT: (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) tetrazolium; N-HATU: N-[(Dimethylamino)-1H-
1,2,3-triazolo[4,5-b]pyridine-1ylmethylene]-N-methylmethanaminium-hexafluorophosphate N-oxide; N-
HBTU: N-[(1HBenzotriazol-1-yl)-(dimethylamino)methylene]-N-methylmethanaminium 
hexafluorophosphate N-oxide; Pbf: 2,2,4,6,7-Pentamethyldihydrobenzofuran-5-sulfonyl; SD: standard 
deviation; SPPS: solid phase peptide synthesis; TAMRA: 5-carboxytetramethyl rhodamine; TFA: 












4. General protocol for synthetic procedures 
Peptides TmA, TmR8, TmR4 and AcR4 were synthesized according to classic SPPS of peptides and further details 
are given below. The cage C (Fig. S18) was prepared and purified following the procedure reported in 
literature.1,2 
 
Figure S18. A) Cage C was synthesized according to the procedure reported in the literature.1,2 For clarity, 
only one of the edges of the structure is shown. B) Structure of AcR4C as a representative example of the 
attachment of the peptide to C. Only one peptide is attached to the cage. C) A representation of the peptide-
cage hybrid with a pyranine molecule inside the cage. 
4.1. Synthesis and characterization of the peptides TmA, TmR8, TmR4 and AcR4 
All peptides were synthesized by manual Fmoc solid-phase peptide synthesis on a 2-Chlorotrityl chloride 
resin (1.14 mmol/g). The first coupling was performed in CH2Cl2 using DIEA as base whereas for the 
following couplings HBTU as activator, DIEA as base, and DMF as solvent were used. The deprotection of 
the temporal Fmoc protecting group was performed by treating the resin with 20% piperidine in DMF. 5(6)-
carboxytetramethylrhodamine (TAMRA) was coupled using 3 equivalents (0.15 mmol, 64.5 mg), 3 
equivalents of HATU and 5 equivalents of DIEA 0.2 M in DMF for 60 min. Acetylation of the N-terminal 
group of AcR4 was performed by standard Fmoc removal conditions (20% piperidine in DMF) followed by 
treatment with a solution of acetic anhydride and 2,6- lutidine (1:1, 2 mL) for 30 min. 
Cleavage/deprotection step was performed by treatment of the resin-bound peptide for 2 h with the following 
cleavage cocktail: 900 µL TFA, 50 µL CH2Cl2, 25 µL H2O and 25 µL TIS (1 mL of cocktail/40 mg resin) 
and peptides were precipitated in Et2O. 
4.1.1. Synthesis and characterization of peptide TmA 
The synthesis of the peptide TmA (TAMRA-Ahx-R-R-L-R-R-L-L-R-R-L-L-R-A-Ahx-O2Oc-OH) was 
performed following the above methodology. TmA was obtained after RP-HPLC purification [Phenomenex 
Luna C18(2) 100A column, H2O (0.1% TFA)/ CH3CN (0.1% TFA) 95:5→5:95 (5→35 min)] with an overall 
yield of 12%. Rt 8.0 min [RP-HPLC Agilent SB-C18 column, H2O (0.1% TFA)/ CH3CN (0.1% TFA) 
95:5→5:95 (0→12 min)] (Fig. S19). MS (ESI, H2O) m/z: calcd for C118H204N39O23 [M+5H]5+: 507.3, found: 
507.5; calcd for C118H203N39O23 [M+4H]4+: 633.9, found 634.0; calcd for C120H203N39O25F3 [M+3H+TFA]3+: 
 
S19	
882.9, found: 883.0; calcd for C122H204N39O27F6 [M+3H+2TFA]3+: 920.9, found: 920.9; calcd for 
C122H203N39O27F6 [M+2H+2TFA]2+ : 1380.8, found: 1380.7. 
 
Figure S19. Representation of the HPLC-MS for TmA. a) HPLC chromatogram (λabs = 550 nm) of TmA and 
b) ESI-MS recorded at 8.0 min of TmA. 
 
4.1.2. Synthesis and characterization of peptide TmR8 
The synthesis of the peptide TmR8 (TAMRA-Ahx-R-R-R-R-R-R-R-R-Ahx-O2Oc-OH) was performed 
following the above methodology. TmR8 was obtained after RP-HPLC purification [Phenomenex Luna 
C18(2) 100A column, H2O (0.1% TFA)/ CH3CN (0.1% TFA) 95:5→5:95 (5→35 min)] with an overall yield 
of 12%. Rt 10.9 min [RP-HPLC Agilent SB-C18 column, H2O (0.1% TFA)/ CH3CN (0.1% TFA) 75:5→5:75 
(0→21 min)] (Fig. S20). MS (ESI, H2O) m/z: calcd for C91H156N37O18 [M+5H]5+: 411.0, found: 411.3; calcd 
for C93H156N37O20F3 [M+4H+TFA]4+: 542.1, found: 542.3; calcd for C93H155N37O20F3 [M+3H+TFA]3+: 722.4, 
found: 722.9; calcd for C95H156N37O22F6 [M+3H+2TFA]3+: 760.4, found: 760.6; calcd for C97H156N37O24F9 
[M+2H+3TFA]2+: 1197.1, found: 1197.6. 
 
Figure S20. Representation of the HPLC-MS for TmR8. a) HPLC chromatogram (λobs = 550 nm) of TmR8 and 










4.1.3. Synthesis and characterization of peptide TmR4 
The synthesis of the peptide TmR4 (TAMRA-Ahx-R-R-R-R-Ahx-O2Oc-OH) was performed following the 
above methodology. TmR4 was obtained after RP-HPLC purification [Phenomenex Luna C18(2) 100A 
column, H2O (0.1% TFA)/ CH3CN (0.1% TFA) 95:5→5:95 (5→35 min)] with an overall yield of 12%. Rt 
11.1 min [RP-HPLC Agilent SB-C18 column, H2O (0.1% TFA)/ CH3CN (0.1% TFA) 75:5→5:75 (0→21 
min)] (Fig. S21). MS (ESI, H2O) m/z: calcd for C67H107N21O14 [M+4H]4+: 357.5, found: 357.8; calcd for 
C67H106N21O14 [M+3H]3+: 476.3, found: 476.5; calcd for C67H105N21O14 [M+2H]2+: 713.9, found: 714.0. 
 
 
Figure S21. Representation of the HPLC-MS for TmR4. a) HPLC chromatogram (λobs = 550 nm) of TmR4 and 
b) ESI-MS recorded at 11.1 min of TmR4. 
 
4.1.4. Synthesis and characterization of peptide AcR4 
The synthesis of the peptide AcR4 (Ac-R-R-R-R-Ahx-O2Oc-OH) was performed following the above 
methodology. AcR4 was obtained after RP-HPLC purification [Phenomenex Luna C18(2) 100A column, H2O 
(0.1% TFA)/ CH3CN (0.1% TFA) 95:5→5:95 (0→5 min)] with an overall yield of 12%. Rt 2.9 min [RP-
HPLC Agilent SB-C18 column, H2O (0.1% TFA)/ CH3CN (0.1% TFA) 95:5→5:95 (0→5 min)] (Fig. S22). 
MS (ESI, H2O) m/z: calcd for C38H77N18O10 [M+3H]3+: 315.2, found: 315.3; calcd for C38H76N18O10 
[M+2H]2+: 472.3, found: 472.4; calcd for C38H75N18O10 [M+H]+: 943.6, found: 943.6; calcd for 




Figure S22. Representation of the HPLC-MS for AcR4 a) HPLC chromatogram (λobs = 222 nm) of AcR4 and b) 
ESI-MS recorded at 2.9 min of AcR4. 
4.2. Synthesis and characterization of peptides TmAC, TmR8C, TmR4C and AcR4C 
For the synthesis of the supramolecular carriers the TmA, TmR8, TmR4 and AcR4 peptides were solved in DMF 
(0.1 mM, 100 µL) before HATU (1 equiv) and DIEA (10 equiv) were added to the solution. This solution 
was added to a 0.1 mM solution of the cage C, adding 1 equiv of peptide to 1 equiv of C, and the reaction 
mixture was left stirring overnight.  
4.2.1. Synthesis and characterization of peptide TmAC 
TmA was solved in 100 µL of DMF (10 mg, 0.004 mM) before HATU (6 mg, 0.016 mmol, 4 equiv) and 
DIEA (6.91 µL, 0.040 mmol, 10 equiv) were added to the solution of the cage C in 164 µL of DMF (7.3 mg, 
0.004 mmol, 1 equiv). The reaction was left stirring overnight and the resulting reaction mixture was purified 
by RP-HPLC [Phenomenex Luna C18(2) 100A column, H2O (0.1% TFA)/ CH3CN (0.1% TFA) 
85:15→55:45 (30 min)]. TmAC was obtained after sample lyophilization as a purple solid (2 mg, 12 %). Rt 
18.7 min (Fig. S23). MS (ESI, H2O) m/z: calcd for C234H356N67O32F12 [M+7H+4TFA+2H2O]7+: 692.4, found: 
690.9 [M+7H+4TFA+2H2O]+7; calcd for C230H356N67O29F6  [M+7H+2TFA+3H2O]7+:662.4, found: 662.4. 
 
Figure S23. Representation of the HPLC-MS for TmAC. a) HPLC chromatogram (λobs = 550 nm) of 












4.2.2. Synthesis and characterization of peptide TmR8C 
TmR8 was solved in 100 µL of DMF (10 mg, 0.005 mM) before HATU (7.4 mg, 0.019 mmol, 4 equiv) and 
DIEA (8.5 µL, 0.05 mmol, 10 equiv) were added to the solution of the cage C in 225 µL of DMF (9.0 mg, 
0.005 mmol, 1 equiv). The reaction was left stirring overnight and the resulting reaction mixture was purified 
by RP-HPLC.TmR8C was obtained after RP-HPLC purification [Phenomenex Luna C18(2) 100A column, 
H2O (0.1% TFA)/ CH3CN (0.1% TFA) 85:15→55:45 (30 min)] with an overall yield of 13% (2.5 mg). Rt 
14.3 min (Fig. S24). MS (ESI, H2O) m/z: calcd for C201H310N65O22F3 [M+10H+TFA+3H2O]10+: 404.5, found: 
404.0 [M+10H+TFA+3H2O]+10; calcd for C201H308N65O22F3 [M+8H+TFA+3H2O]8+: 505.4, found: 504.8; 
calcd for C201H306N65O22F3 [M+6H+TFA+3H2O]6+: 673.6, found: 672.7; calcd for C203H300N65O21F6Na 
[M+5H+2TFA+Na]5+: 824.7, found: 824.7. 
 
Figure S24. Representation of the HPLC-MS for TmR8C a) HPLC chromatogram (λobs = 550 nm) of TmR8C 
and b) ESI-MS recorded at 4.65 min of TmR8C. c) UV-Vis spectrum at 4.65 minutes corresponding to TmR8C. 
 
4.2.3. Synthesis and characterization of peptide TmR4C 
TmR4 was solved in 100 µL of DMF (12.9 mg, 0.007 mM) before HATU (10.7 mg, 0.028 mmol, 4 equiv) and 
DIEA (12.3 µL, 0.07 mmol, 10 equiv) were added to the solution of the cage C in 368 µL of DMF (9.0 mg, 
0.005 mmol, 1 equiv). The reaction was left stirring overnight and the resulting reaction mixture was purified 
by RP-HPLC.TmR4C was obtained after RP-HPLC purification [Phenomenex Luna C18(2) 100A column, 
H2O (0.1% TFA)/ CH3CN (0.1% TFA) 85:15→55:45 (30 min)] with an overall yield of 13% (2.5 mg). Rt 
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11.9 min (Fig. S25). MS (ESI, H2O) m/z: calcd for C175H249N49O13 [M+4H]4+: 811.5, found: 812.4; calcd for 
C179H259N49O18F6 [M+10H+2TFA+H2O]10+: 349.8, found: 349.7; calcd for C183H259N49O22F12 
[M+8H+4TFA+H2O]8+: 465.5, found: 465.3. 
 
Figure S25. HPLC-MS spectra of TmR4C, a) chromatogram observed for λ=550 nm, b) ESI-MS spectrum 
corresponding to t = 4.73 minutes which corresponds to TmR4C and c) UV-Vis spectrum at 4.73 minutes 
corresponding to TmR4C. 
 
4.2.4. Synthesis and characterization of peptide AcR4C 
AcR4 was solved in 100 µL of DMF (10.3 mg, 0.011 mM) before HATU (4 mg, 0.011 mmol, 1 equiv) and 
DIEA (14.1 µL, 0.109 mmol, 10 equiv) were added to the solution of the cage C in 368 µL of DMF (20 mg, 
0.011 mmol, 1 equiv). The reaction was left stirring overnight and the resulting reaction mixture was purified 
by RP-HPLC. AcR4C was obtained after RP-HPLC purification [Luna C18(2) 100A column, H2O (0.1% 
TFA)/ CH3CN (0.1% TFA) 85:15→55:45 (30 min)] with an overall yield of 10% (3.1 mg). Rt 10.5 min (Fig. 
S26). MS (ESI, H2O) m/z: calcd for C152H227N46O15F9 [M+8H+3TFA]8+: 388.6, found: 387.5; calcd for 







Figure S26. HPLC-MS spectra of AcR4C, a) chromatogram observed for λ=222 nm, b) ESI-MS spectrum 
corresponding to t = 4.01 minutes which corresponds to AcR4C and c) UV-Vis spectrum at 4.01 minutes 
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